Home Journals The Decline of the Experimental Paradigm During the COVID-19 Pandemic: A Template...

The Decline of the Experimental Paradigm During the COVID-19 Pandemic: A Template for the Future

  • Johns Hopkins Coronavirus Resource Center. https://coronavirus.jhu.edu/(online access: 16/08/2020)

  • Blocking information on COVID-19 can fuel the spread of misinformation.

    Nature. 2020; 580 (): 306

  • The online competition between pro- and anti-vaccination views.

    Nature. 2020;

  • Scientists are drowning in COVID-19 papers. Can new tools keep them afloat?.

    Science. 2020;

    • White R.G.
    • Hakim A.J.
    • Salganik M.J.
    • Spiller M.W.
    • Johnston L.G.
    • Kerr L.
    • Kendall C.
    • Drake A.
    • Wilson D.
    • Orroth K.
    • Egger M.
    • Hladik W.

    Strengthening the Reporting of Observational Studies in Epidemiology for respondent-driven sampling studies: “STROBE-RDS” statement.

    J Clin Epidemiol. 2015;

    • Sharma M.
    • Scarr S.
    • Kelland K.

    Speed Science: The risks of swiftly spreading coronavirus research.

    Reuters. 2020;

    • Trogen B.
    • Oshinsky D.
    • Caplan A.

    Adverse Consequences of Rushing a SARS-CoV-2 Vaccine: Implications for Public Trust.

    Jama. 2020;

  • Reliable assessment of the effects of treatment on mortality and major morbidity, I: clinical trials.

    Lancet. 2001; 357: 373-380

  • Which clinical studies provide the best evidence? The best RCT still trumps the best observational study.

    Bmj. 2000; 321: 255-256

    • Rush C.J.
    • Campbell R.T.
    • Jhund P.S.
    • Petrie M.C.
    • McMurray J.J.V.

    Association is not causation: treatment effects cannot be estimated from observational data in heart failure.

    Eur Heart J. 2018; 39: 3417-3438

  • Small studies: strengths and limitations.

    in: Eur Respir J. 32. 2008: 1141-1143 ()

    • Wang M.T.
    • Bolland M.J.
    • Gamble G.
    • Grey A.

    Media Coverage, Journal Press Releases and Editorials Associated with Randomized and Observational Studies in High-Impact Medical Journals: A Cohort Study.

    PLoS One. 2015; 10e0145294

    • Guertin J.R.
    • Rahme E.
    • Dormuth C.R.
    • LeLorier J.

    Head to head comparison of the propensity score and the high-dimensional propensity score matching methods.

    BMC Med Res Methodol. 2016; 16: 22

  • The design versus the analysis of observational studies for causal effects: parallels with the design of randomized trials.

    Stat Med. 2007; 26: 20-36

    • Kaplan R.M.
    • Chambers D.A.
    • Glasgow R.E.

    Big data and large sample size: a cautionary note on the potential for bias.

    Clin Transl Sci. 2014; 7: 342-346

    • Freemantle N.
    • Marston L.
    • Walters K.
    • Wood J.
    • Reynolds M.R.
    • Petersen I.

    Making inferences on treatment effects from real world data: propensity scores, confounding by indication, and other perils for the unwary in observational research.

    Bmj. 2013; 347: f6409

  • Bias and causal associations in observational research.

    Lancet. 2002; 359: 248-252

  • Discussing hidden bias in observational studies.

    Ann Intern Med. 1991; 115: 901-905

    • Dickerman B.A.
    • García-Albéniz X.
    • Logan R.W.
    • Denaxas S.
    • Hernán M.A.

    Avoidable flaws in observational analyses: an application to statins and cancer.

    Nat Med. 2019; 25: 1601-1606

  • Win-Win: Reconciling Social Epidemiology and Causal Inference.

    Am J Epidemiol. 2020; 189: 167-170

    • Blagoev K.B.
    • Wilkerson J.
    • Fojo T.

    Hazard ratios in cancer clinical trials–a primer.

    Nat Rev Clin Oncol. 2012; 9 (): 178-183

    • Geleris J.
    • Sun Y.
    • Platt J.
    • Zucker J.
    • Baldwin M.
    • Hripcsak G.
    • Labella A.
    • Manson D.
    • Kubin C.
    • Barr R.G.
    • Sobieszczyk M.E.
    • Schluger N.W.

    Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19.

    N Engl J Med. 2020;

    • Mehra M.R.
    • Desai S.S.
    • Kuy S.
    • Henry T.D.
    • Patel A.N.

    Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19.

    N Engl J Med. 2020;

    • Shang L.
    • Zhao J.
    • Hu Y.
    • Du R.
    • Cao B.

    On the use of corticosteroids for 2019-nCoV pneumonia.

    Lancet. 2020; 395: 683-684

    • Richardson P.
    • Griffin I.
    • Tucker C.
    • Smith D.
    • Oechsle O.
    • Phelan A.
    • Stebbing J.

    Baricitinib as potential treatment for 2019-nCoV acute respiratory disease.

    Lancet. 2020; 395: e30-e31

    • Rosenberg E.S.
    • Dufort E.M.
    • Udo T.
    • Wilberschied L.A.
    • Kumar J.
    • Tesoriero J.
    • Weinberg P.
    • Kirkwood J.
    • Muse A.
    • DeHovitz J.
    • Blog D.S.
    • Hutton B.
    • Holtgrave D.R.
    • Zucker H.A.

    Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State.

    Jama. 2020;

    • Shen C.
    • Wang Z.
    • Zhao F.
    • Yang Y.
    • Li J.
    • Yuan J.
    • Wang F.
    • Li D.
    • Yang M.
    • Xing L.
    • Wei J.
    • Xiao H.
    • Qu J.
    • Qing L.
    • Chen L.
    • Xu Z.
    • Peng L.
    • Li Y.
    • Zheng H.
    • Chen F.
    • Huang K.
    • Jiang Y.
    • Liu D.
    • Zhang Z.
    • Liu Y.
    • Liu L.

    Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.

    Jama. 2020;

    • Elharrar X.
    • Trigui Y.
    • Dols A.M.
    • Touchon F.
    • Martinez S.
    • Prud’homme E.
    • Papazian L.

    Use of Prone Positioning in Nonintubated Patients With COVID-19 and Hypoxemic Acute Respiratory Failure.

    Jama. 2020;

    • Grein J.
    • Ohmagari N.
    • Shin D.
    • Diaz G.
    • Asperges E.
    • Castagna A.
    • Feldt T.
    • Green G.
    • Green M.L.
    • Lescure F.X.
    • Nicastri E.
    • Oda R.
    • Yo K.
    • Quiros-Roldan E.
    • Studemeister A.
    • Redinski J.
    • Ahmed S.
    • Bernett J.
    • Chelliah D.
    • Chen D.
    • Chihara S.
    • Cohen S.H.
    • Cunningham J.
    • D’Arminio Monforte 0.
    • Ismail S.
    • Kato H.
    • Lapadula G.
    • L’Her E.
    • Maeno T.
    • Majumder S.
    • Massari M.
    • Mora-Rillo M.
    • Mutoh Y.
    • Nguyen D.
    • Verweij E.
    • Zoufaly A.
    • Osinusi A.O.
    • DeZure A.
    • Zhao Y.
    • Zhong L.
    • Chokkalingam A.
    • Elboudwarej E.
    • Telep L.
    • Timbs L.
    • Henne I.
    • Sellers S.
    • Cao H.
    • Tan S.K.
    • Winterbourne L.
    • Desai P.
    • Mera R.
    • Gaggar A.
    • Myers R.P.
    • Brainard D.M.
    • Childs R.
    • Flanigan T.

    Compassionate Use of Remdesivir for Patients with Severe Covid-19.

    N Engl J Med. 2020;

    • Sartini C.
    • Tresoldi M.
    • Scarpellini P.
    • Tettamanti A.
    • Carcò F.
    • Landoni G.
    • Zangrillo A.

    Respiratory Parameters in Patients With COVID-19 After Using Noninvasive Ventilation in the Prone Position Outside the Intensive Care Unit.

    Jama. 2020;

    • de Abajo F.J.
    • Rodríguez-Martín S.
    • Lerma V.
    • Mejía-Abril G.
    • Aguilar M.
    • García-Luque A.
    • Laredo L.
    • Laosa O.
    • Centeno-Soto G.A.
    • Ángeles Gálvez M.
    • Puerro M.
    • González-Rojano E.
    • Pedraza L.
    • de Pablo I.
    • Abad-Santos F.
    • Rodríguez-Mañas L.
    • Gil M.
    • Tobías A.
    • Rodríguez-Miguel A.
    • Rodríguez-Puyol D.

    Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study.

    Lancet. 2020;

    • Mehra M.
    • Desai S.
    • Ruschitzka F.
    • Patel A.

    Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis.

    Lancet. 2020;

  • Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial.

    Lancet. 2020;

    • Thomas L.E.
    • Bonow R.O.
    • Pencina M.J.

    Understanding Observational Treatment Comparisons in the Setting of Coronavirus Disease 2019 (COVID-19).

    JAMA Cardiol. 2020;

    • Fosbøl E.L.
    • Butt J.H.
    • Østergaard L.
    • Andersson C.
    • Selmer C.
    • Kragholm K.
    • Schou M.
    • Phelps M.
    • Gislason G.H.
    • Gerds T.A.
    • Torp-Pedersen C.
    • Køber L.

    Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With COVID-19 Diagnosis and Mortality.

    Jama. 2020; 324: 168-177

    • Cao B.
    • Wang Y.
    • Wen D.
    • Liu W.
    • Wang J.
    • Fan G.
    • Ruan L.
    • Song B.
    • Cai Y.
    • Wei M.
    • Li X.
    • Xia J.
    • Chen N.
    • Xiang J.
    • Yu T.
    • Bai T.
    • Xie X.
    • Zhang L.
    • Li C.
    • Yuan Y.
    • Chen H.
    • Li H.
    • Huang H.
    • Tu S.
    • Gong F.
    • Liu Y.
    • Wei Y.
    • Dong C.
    • Zhou F.
    • Gu X.
    • Xu J.
    • Liu Z.
    • Zhang Y.
    • Shang L.
    • Wang K.
    • Li K.
    • Zhou X.
    • Dong X.
    • Qu Z.
    • Lu S.
    • Hu X.
    • Ruan S.
    • Luo S.
    • Wu J.
    • Peng L.
    • Cheng F.
    • Pan L.
    • Zou J.
    • Jia C.
    • Liu X.
    • Wang S.
    • Wu X.
    • Ge Q.
    • He J.
    • Zhan H.
    • Qiu F.
    • Guo L.
    • Huang C.
    • Jaki T.
    • Hayden F.G.
    • Horby P.W.
    • Zhang D.
    • Wang C.

    A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.

    N Engl J Med. 2020; 382: 1787-1799

    • Hung I.F.
    • Lung K.C.
    • Tso E.Y.
    • Liu R.
    • Chung T.W.
    • Chu M.Y.
    • Ng Y.Y.
    • Lo J.
    • Chan J.
    • Tam A.R.
    • Shum H.P.
    • Chan V.
    • Wu A.K.
    • Sin K.M.
    • Leung W.S.
    • Law W.L.
    • Lung D.C.
    • Sin S.
    • Yeung P.
    • Yip C.C.
    • Zhang R.R.
    • Fung A.Y.
    • Yan E.Y.
    • Leung K.H.
    • Ip J.D.
    • Chu A.W.
    • Chan W.M.
    • Ng A.C.
    • Lee R.
    • Fung K.
    • Yeung A.
    • Wu T.C.
    • Chan J.W.
    • Yan W.W.
    • Chan J.F.
    • Lie A.K.
    • Tsang O.T.
    • Cheng V.C.
    • Que T.L.
    • Lau C.S.
    • Chan K.H.
    • To K.K.
    • Yuen K.Y.

    Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial.

    Lancet. 2020;

  • Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.

    Lancet. May 16, 2020; 395: 1569-1578

  • Remdesivir for the Treatment of Covid-19 — Preliminary Report.

    NEJM. 2020;

    • Goldman J.D.
    • Lye D.C.B.
    • Hui D.S.
    • Marks K.M.
    • Bruno R.
    • Montejano R.
    • Spinner C.D.
    • Galli M.
    • Ahn M.Y.
    • Nahass R.G.
    • Chen Y.S.
    • SenGupta D.
    • Hyland R.H.
    • Osinusi A.O.
    • Cao H.
    • Blair C.
    • Wei X.
    • Gaggar A.
    • Brainard D.M.
    • Towner W.J.
    • Muñoz J.
    • Mullane K.M.
    • Marty F.M.
    • Tashima K.T.
    • Diaz G.
    • Subramanian A.

    Remdesivir for 5 or 10 Days in Patients with Severe Covid-19.

    N Engl J Med. 2020;

    • Boulware D.R.
    • Pullen M.F.
    • Bangdiwala A.S.
    • Pastick K.A.
    • Lofgren S.M.
    • Okafor E.C.
    • Skipper C.P.
    • Nascene A.A.
    • Nicol M.R.
    • Abassi M.
    • Engen N.W.
    • Cheng M.P.
    • LaBar D.
    • Lother S.A.
    • MacKenzie L.J.
    • Drobot G.
    • Marten N.
    • Zarychanski R.
    • Kelly L.E.
    • Schwartz I.S.
    • McDonald E.G.
    • Rajasingham R.
    • Lee T.C.
    • Hullsiek K.H.

    A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19.

    N Engl J Med. 2020;

    • Li L.
    • Zhang W.
    • Hu Y.
    • Tong X.
    • Zheng S.
    • Yang J.
    • Kong Y.
    • Ren L.
    • Wei Q.
    • Mei H.
    • Hu C.
    • Tao C.
    • Yang R.
    • Wang J.
    • Yu Y.
    • Guo Y.
    • Wu X.
    • Xu Z.
    • Zeng L.
    • Xiong N.
    • Chen L.
    • Man N.
    • Liu Y.
    • Xu H.
    • Deng E.
    • Zhang X.
    • Li C.
    • Wang C.
    • Su S.
    • Zhang L.
    • Wu Y.
    • Liu Z.

    Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial.

    Jama. 2020;

    • Horby P.
    • Lim W.S.
    • Emberson J.R.
    • Mafham M.
    • Bell J.L.
    • Linsell L.
    • Staplin N.
    • Brightling C.
    • Ustianowski A.
    • Elmahi E.
    • Prudon B.
    • Green C.
    • Felton T.
    • Chadwick D.
    • Rege K.
    • Fegan C.
    • Chappell L.C.
    • Faust S.N.
    • Jaki T.
    • Jeffery K.
    • Montgomery A.
    • Rowan K.
    • Juszczak E.
    • Baillie J.K.
    • Haynes R.
    • Landray M.J.

    Dexamethasone in Hospitalized Patients with Covid-19 – Preliminary Report.

    N Engl J Med. 2020;

  • signatories, J. W. o. t. b. o., An open letter to Mehra et al and The Lancet. 2020.

    • Hernandez A.V.
    • Roman Y.M.
    • Pasupuleti V.
    • Barboza J.J.
    • White C.M.

    Hydroxychloroquine or Chloroquine for Treatment or Prophylaxis of COVID-19: A Living Systematic Review.

    Ann Intern Med. 2020;

    • Alexander P.E.
    • Debono V.B.
    • Mammen M.J.
    • Iorio A.
    • Aryal K.
    • Deng D.
    • Brocard E.
    • Alhazzani W.

    COVID-19 coronavirus research has overall low methodological quality thus far: case in point for chloroquine/hydroxychloroquine.

    J Clin Epidemiol. 2020;

    • North C.M.
    • Dougan M.L.
    • Sacks C.A.

    Improving Clinical Trial Enrollment – In the Covid-19 Era and Beyond.

    N Engl J Med. 2020;

  • Research in the Context of a Pandemic.

    N Engl J Med. 2020;

  • An organizational analysis of the World Health Organization: narrowing the gap between promise and performance.

    Soc Sci Med. 1995; 40: 731-742

    • Bloom B.R.
    • Farmer P.E.
    • Rubin E.J.

    WHO’s Next – The United States and the World Health Organization.

    N Engl J Med. 2020;

    • Devaux C.A.
    • Rolain J.M.
    • Colson P.
    • Raoult D.

    New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?.

    Int J Antimicrob Agents. 2020; 105938

  • Global regulators work towards alignment on policy approaches and regulatory flexibility during COVID-19 – update #3. https://www.ema.europa.eu/en/news/global-regulators-work-towards-alignment-policy-approaches-regulatory-flexibility-during-covid-19-2(online access: 16/08/2020).

    • Armstrong P.W.
    • Naylor C.D.

    Counteracting Health Misinformation: A Role for Medical Journals?.

    Jama. 2019; 321: 1863-1864

    • Chou W.S.
    • Oh A.
    • Klein W.M.P.

    Addressing Health-Related Misinformation on Social Media.

    Jama. 2018; 320: 2417-2418

  • Protecting the Value of Medical Science in the Age of Social Media and “Fake News”.

    Jama. 2018; 320: 2415-2416

    • Vosoughi S.
    • Roy D.
    • Aral S.

    The spread of true and false news online.

    Science. 2018; 359: 1146-1151

  • In India, Hindu pride boosts pseudoscience.

    Science. 2019; 363 (): 679-680

    • Broniatowski D.A.
    • Jamison A.M.
    • Qi S.
    • AlKulaib L.
    • Chen T.
    • Benton A.
    • Quinn S.C.
    • Dredze M.

    Weaponized Health Communication: Twitter Bots and Russian Trolls Amplify the Vaccine Debate.

    Am J Public Health. 2018; 108: 1378-1384

  • Medical Education in the Era of Alternative Facts.

    N Engl J Med. 2017; 377: 607-609

  • Infographic: The Best And Worst Science News Sites.

    American Council on Science and Health. 2017;

  • Roth, Y.; Achuthan, A., Building rules in public: Our approach to synthetic & manipulated media. https://blog.twitter.com/en_us/topics/company/2020/new-approach-to-synthetic-and-manipulated-media.html(online access: 16/08/2020).

    • Fast S.M.
    • Kim L.
    • Cohn E.L.
    • Mekaru S.R.
    • Brownstein J.S.
    • Markuzon N.

    Predicting social response to infectious disease outbreaks from internet-based news streams.

    Ann Oper Res. 2018; 263 : 551-564

    • Hill J.A.
    • Agewall S.
    • Baranchuk A.
    • Booz G.W.
    • Borer J.S.
    • Camici P.G.
    • Chen P.S.
    • Dominiczak A.F.
    • Erol C.
    • Grines C.L.
    • Gropler R.
    • Guzik T.J.
    • Heinemann M.K.
    • Iskandrian A.E.
    • Knight B.P.
    • London B.
    • Luscher T.F.
    • Metra M.
    • Musunuru K.
    • Nallamothu B.K.
    • Natale A.
    • Saksena S.
    • Picard M.H.
    • Rao S.V.
    • Remme W.J.
    • Rosenson R.S.
    • Sweitzer N.K.
    • Timmis A.
    • Vrints C.

    Medical Misinformation: Vet the Message!.

    Eur Heart J. 2019; 40: 404-405

    • Atkins D.
    • Best D.
    • Briss P.A.
    • Eccles M.
    • Falck-Ytter Y.
    • Flottorp S.
    • Guyatt G.H.
    • Harbour R.T.
    • Haugh M.C.
    • Henry D.
    • Hill S.
    • Jaeschke R.
    • Leng G.
    • Liberati A.
    • Magrini N.
    • Mason J.
    • Middleton P.
    • Mrukowicz J.
    • O’Connell D.
    • Oxman A.D.
    • Phillips B.
    • Schünemann H.J.
    • Edejer T.
    • Varonen H.
    • Vist G.E.
    • Williams Jr., J.W.
    • Zaza S.

    Grading quality of evidence and strength of recommendations.

    Bmj. 2004; 328: 1490

    • Ladeiras-Lopes R.
    • Clarke S.
    • Vidal-Perez R.
    • Alexander M.
    • Luscher T.F.

    Twitter promotion predicts citation rates of cardiovascular articles: a preliminary analysis from the ESC Journals Randomized Study.

    Eur Heart J. 2020;

    • Thamman R.
    • Gulati M.
    • Narang A.
    • Utengen A.
    • Mamas M.A.
    • Bhatt D.L.

    Twitter-based learning for continuing medical education?.

    Eur Heart J. 2020;

  • Nudge: Improving Decisions about Health, Wealth, and Happiness.

    2008

    • van Eck N.J.
    • Waltman L.
    • van Raan A.F.
    • Klautz R.J.
    • Peul W.C.

    Citation analysis may severely underestimate the impact of clinical research as compared to basic research.

    PLoS One. 2013; 8: e62395

  • Moderna Announces Positive Interim Phase 1 Data for its mRNA Vaccine (mRNA-1273) Against Novel Coronavirus. https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-positive-interim-phase-1-data-its-mrna-vaccine/(online access: 16/08/2020).

  • In Race for a Coronavirus Vaccine, an Oxford Group Leaps Ahead. https://www.nytimes.com/2020/04/27/world/europe/coronavirus-vaccine-update-oxford.html(online access: 16/08/2020).

  • Haseltine, W.Rush to share good news on COVID-19 drugs is undermining science. https://www.washingtonpost.com/opinions/2020/05/19/rush-share-good-news-covid-19-drugs-is-undermining-science/(online access: 16/08/2020).



  • Source link